Efficacy of immune checkpoint inhibitors in paediatric, adolescent and young adults with primary refractory or relapsed classical Hodgkin lymphoma: A national multicentre real-world study.
AI interpretation is pending for this paper.
Open original publication →What the AI sees
Not AI summarized yet.
Research significance
Pending deeper interpretation.
Source abstract
Classical Hodgkin lymphoma (cHL) is the most frequent lymphoma in children, adolescents and young adults (CAYA). Despite therapeutic advances, around 15% of patients relapse or have refractory (R/R) disease. Conventional salvage regimens remain effective but are associated with substantial long-term toxicity. Immune checkpoint inhibitors (CPIs), such as nivolumab and pembrolizumab, and the anti-CD30 antibody-drug conjugate brentuximab vedotin (BV) have recently demonstrated encouraging efficacy with improved safety. We conducted a retrospective, multicentre nationwide study to assess the real-world efficacy of CPI in CAYA patients (<18 years) with R/R cHL treated outside clinical trials in France between August 2015 and May 2023. Twenty-seven patients from 11 centres were included. Median age at CPI initiation was 16 years; 70% had advanced disease. Prior treatments included BV (44%), autologous stem cell transplantation (22%) and allogeneic transplantation (4%). Nivolumab was used in 89%, frequently combined with BV (67%). The overall response rate was 93%, with 63% achieving complete metabolic response. After a median follow-up of 28 months, 3-year progression-free survival and overall survival were 48% and 95%, respectively, and toxicities were manageable. These findings strongly support CPI as a highly effective and well-tolerated treatment option for the CAYA population with R/R cHL even in heavily pretreated patients.